A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS): Results from ECOG-ACRIN E1Z11
CONCLUSION: We were unable to prospectively validate candidate SNPs previously associated with AI discontinuation due to AIMSS. Future analyses will explore additional genetic markers, PRO predictors of AIMSS, and differences by race.PMID:38640040 | DOI:10.1158/1078-0432.CCR-23-2137 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 19, 2024 Category: Cancer & Oncology Authors: Vered Stearns Opeyemi A Jegede Victor Tsu-Shih Chang Todd C Skaar Jeffrey L Berenberg Ranveer Nand Atif Shafqat Nisha Lassi Jacobs William Luginbuhl Paul Gilman Al B Benson Judie R Goodman Gary L Buchschacher N Lynn Henry Charles L Loprinzi Patrick J Flyn Source Type: research
A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS): Results from ECOG-ACRIN E1Z11
CONCLUSION: We were unable to prospectively validate candidate SNPs previously associated with AI discontinuation due to AIMSS. Future analyses will explore additional genetic markers, PRO predictors of AIMSS, and differences by race.PMID:38640040 | DOI:10.1158/1078-0432.CCR-23-2137 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 19, 2024 Category: Cancer & Oncology Authors: Vered Stearns Opeyemi A Jegede Victor Tsu-Shih Chang Todd C Skaar Jeffrey L Berenberg Ranveer Nand Atif Shafqat Nisha Lassi Jacobs William Luginbuhl Paul Gilman Al B Benson Judie R Goodman Gary L Buchschacher N Lynn Henry Charles L Loprinzi Patrick J Flyn Source Type: research
A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS): Results from ECOG-ACRIN E1Z11
CONCLUSION: We were unable to prospectively validate candidate SNPs previously associated with AI discontinuation due to AIMSS. Future analyses will explore additional genetic markers, PRO predictors of AIMSS, and differences by race.PMID:38640040 | DOI:10.1158/1078-0432.CCR-23-2137 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 19, 2024 Category: Cancer & Oncology Authors: Vered Stearns Opeyemi A Jegede Victor Tsu-Shih Chang Todd C Skaar Jeffrey L Berenberg Ranveer Nand Atif Shafqat Nisha Lassi Jacobs William Luginbuhl Paul Gilman Al B Benson Judie R Goodman Gary L Buchschacher N Lynn Henry Charles L Loprinzi Patrick J Flyn Source Type: research
Testosterone and Luteinizing Hormone Predict Semen Parameter Improvement in Infertile Men Treated with Anastrozole
(Source: Fertility and Sterility)
Source: Fertility and Sterility - April 12, 2024 Category: Reproduction Medicine Authors: Bryan Naelitz, Scott Lundy, Amy Nowacki Tags: Letter to the editor Source Type: research
Carotid free-floating thrombus in patients with acute ischaemic stroke and active cancer
We describe two women, each taking tamoxifen for invasive non-metastatic breast cancer, who developed large-vessel occlusion ischaemic strokes. The first had a CFFT 24 hours after receiving intravenous thrombolysis and mechanical thrombectomy; the thrombus completely resolved after 1 week of therapeutic anticoagulation. The second had a tandem occlusion with a CFFT at admission; her neurological deficits rapidly improved after intravenous thrombolysis without needing a mechanical thrombectomy. However, subsequently, under therapeutic anticoagulation, distal migration of the CFFT caused a recurrent large vessel occlusion is...
Source: Practical Neurology - April 4, 2024 Category: Neurology Authors: Rita Monteiro Ventura In ês Freire Jo ão Pedro Marto Source Type: research
Carotid free-floating thrombus in patients with acute ischaemic stroke and active cancer
We describe two women, each taking tamoxifen for invasive non-metastatic breast cancer, who developed large-vessel occlusion ischaemic strokes. The first had a CFFT 24 hours after receiving intravenous thrombolysis and mechanical thrombectomy; the thrombus completely resolved after 1 week of therapeutic anticoagulation. The second had a tandem occlusion with a CFFT at admission; her neurological deficits rapidly improved after intravenous thrombolysis without needing a mechanical thrombectomy. However, subsequently, under therapeutic anticoagulation, distal migration of the CFFT caused a recurrent large vessel occlusion is...
Source: Practical Neurology - April 4, 2024 Category: Neurology Authors: Rita Monteiro Ventura In ês Freire Jo ão Pedro Marto Source Type: research
Anastrozole monotherapy further improves near-adult height after the initial combined treatment with leuprorelin and anastrozole in early-maturing girls with compromised growth prediction: results from the second phase of the GAIL study
ConclusionsIn early-maturing girls with compromised growth potential, the combined treatment with leuprorelin and anastrozole for 2 years or until the age of 11 years resulted in a total gain in height of +9.7 cm when continuing anastrozole monotherapy until the attainment of NAH, as opposed to +7.4 cm if they do not continue with the anastrozole monotherapy and +3.6 cm when treated with leuprorelin alone. Thus, the combined intervention ends at the shortest distance from the target height if continued with anastrozole monotherapy until BA 14 years. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - April 2, 2024 Category: Endocrinology Source Type: research
Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis
Conclusions: Our results suggest that, despite statistically significant results, EXE and LET may not be sufficient to cause severe dyslipidemia in patients without cardiovascular comorbidities according to the AHA/ACC Guideline on the Management of Blood Cholesterol. However, the results may raise the question of monitoring the effects of AIs in patients, especially those with pre-existing cardiovascular risk factors such as dyslipidemia.PMID:38542042 | DOI:10.3390/jcm13061818 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 28, 2024 Category: Cancer & Oncology Authors: B álint Bérczi Nelli Farkas P éter Hegyi Barbara T óth Dezs ő Csupor Bal ázs Németh Anita Luk ács L ászló Márk Czumbel Be áta Kerémi Istv án Kiss Andrea Szab ó G ábor Varga G ábor Gerber Zolt án Gyöngyi Source Type: research
Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis
Conclusions: Our results suggest that, despite statistically significant results, EXE and LET may not be sufficient to cause severe dyslipidemia in patients without cardiovascular comorbidities according to the AHA/ACC Guideline on the Management of Blood Cholesterol. However, the results may raise the question of monitoring the effects of AIs in patients, especially those with pre-existing cardiovascular risk factors such as dyslipidemia.PMID:38542042 | DOI:10.3390/jcm13061818 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 28, 2024 Category: Cancer & Oncology Authors: B álint Bérczi Nelli Farkas P éter Hegyi Barbara T óth Dezs ő Csupor Bal ázs Németh Anita Luk ács L ászló Márk Czumbel Be áta Kerémi Istv án Kiss Andrea Szab ó G ábor Varga G ábor Gerber Zolt án Gyöngyi Source Type: research
Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis
Conclusions: Our results suggest that, despite statistically significant results, EXE and LET may not be sufficient to cause severe dyslipidemia in patients without cardiovascular comorbidities according to the AHA/ACC Guideline on the Management of Blood Cholesterol. However, the results may raise the question of monitoring the effects of AIs in patients, especially those with pre-existing cardiovascular risk factors such as dyslipidemia.PMID:38542042 | PMC:PMC10970985 | DOI:10.3390/jcm13061818 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 28, 2024 Category: Cancer & Oncology Authors: B álint Bérczi Nelli Farkas P éter Hegyi Barbara T óth Dezs ő Csupor Bal ázs Németh Anita Luk ács L ászló Márk Czumbel Be áta Kerémi Istv án Kiss Andrea Szab ó G ábor Varga G ábor Gerber Zolt án Gyöngyi Source Type: research
Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis
Conclusions: Our results suggest that, despite statistically significant results, EXE and LET may not be sufficient to cause severe dyslipidemia in patients without cardiovascular comorbidities according to the AHA/ACC Guideline on the Management of Blood Cholesterol. However, the results may raise the question of monitoring the effects of AIs in patients, especially those with pre-existing cardiovascular risk factors such as dyslipidemia.PMID:38542042 | PMC:PMC10970985 | DOI:10.3390/jcm13061818 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 28, 2024 Category: Cancer & Oncology Authors: B álint Bérczi Nelli Farkas P éter Hegyi Barbara T óth Dezs ő Csupor Bal ázs Németh Anita Luk ács L ászló Márk Czumbel Be áta Kerémi Istv án Kiss Andrea Szab ó G ábor Varga G ábor Gerber Zolt án Gyöngyi Source Type: research
Towards clinical adherence monitoring of oral endocrine breast cancer therapies by LC-HRMS-method development, validation, comparison of four sample matrices, and proof of concept
Anal Bioanal Chem. 2024 Mar 15. doi: 10.1007/s00216-024-05244-6. Online ahead of print.ABSTRACTOral endocrine therapies (OET) for breast cancer treatment need to be taken over a long period of time and are associated with considerable side effects. Therefore, adherence to OET is an important issue and of high clinical significance for breast cancer patients' caregivers. We hypothesized that a new bioanalytical strategy based on liquid chromatography and high-resolution mass spectrometry might be suitable for unbiased adherence monitoring (AM) of OET. Four different biomatrices (plasma, urine, finger prick blood by volumetr...
Source: Analytical and Bioanalytical Chemistry - March 15, 2024 Category: Chemistry Authors: Cathy M Jacobs Julia C Radosa Lea Wagmann Julia S M Zimmermann Askin C Kaya Aylin Ayg ün Tatjana Edel Lisa Stotz Mohamed Ismaeil Erich-Franz Solomayer Markus R Meyer Source Type: research
Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2- advanced breast cancer
CONCLUSIONS: From the perspective of Chinese payers, dalpiciclib plus NSAI appears to be a cost-effective strategy compared with abemaciclib plus NSAI for the first-line treatment of patients with HR+/HER2- ABC in China.PMID:38470447 | DOI:10.1080/14737167.2024.2330542 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - March 12, 2024 Category: Health Management Authors: Hong Juan Chen Tujia Ouyang Lihui Du Ning Li Anna Zhou Zhongqi Zhang HaiLing Xia Zhengzheng Meng Jun Source Type: research
Exploring the Potential of Essential Oil from Plectranthus amboinicus Leaves against Breast Cancer: In vitro and In silico Analysis
Med Oncol. 2024 Feb 24;41(4):81. doi: 10.1007/s12032-024-02325-5.ABSTRACTPlectranthus amboinicus leaves were subjected to hydrodistillation to obtain essential oil (EO). Phytochemical analysis using gas chromatography-mass spectrometry revealed a diverse range of compounds in the EO, with p-cymen-4-ol (18.57%) emerging as the most predominant, followed by isocaryophyllene (12.18%). The in vitro antiproliferative activity of EO against breast cancer was assessed in MCF-7 and MDA-MB-231 cell lines. The MTT assay results revealed that EO showed IC50 values of 42.25 μg/mL and 13.44 μg/mL in MCF-7 cells and 63.67 μg/mL and 2...
Source: Molecular Medicine - February 24, 2024 Category: Molecular Biology Authors: Khushi Gupta Pranay Gautre Avadh Biharee Yogesh Singh Umesh Kumar Patil Shashank Kumar Suresh Thareja Source Type: research
